Understanding Hodgkin Lymphoma with Shana Jacobs, MD
Shana Jacobs, MD gives a deep dive into Hodgkin Lymphoma.
About Dr. Jacobs: Shana Jacobs, Children's National Health System.
Learn More About Hodgkin Lymphoma:
Treatments Under Investigation
Although the cure rate in Hodgkin Lymphoma (HL) is already high, research continues to develop more effective therapies with fewer short- and long-term toxicities. Investigators are also looking for ways to treat the minority of patients who are refractory to treatment and those who relapse. Studies for relapsed/refractory HL are looking at new combinations of targeted therapies or immunotherapies including ibrutinib (Imbruvica), lenalidomide (Revlimid), and a different class of drugs called histone deacetylase (HDAC) inhibitors. Clinical trials are also ongoing for the use of ADCT-301 (camidanlumab tesirine) and anti-CD30-CAR (chimeric antigen receptor) T-cell therapy in relapsed/refractory HL.
To learn more about Hodgkin Lymphoma visit, lymphoma.org/hl.
LEARN MORE!
http://lymphoma.org/
http://facebook.com/lymphomacommunity
http://twitter.com/lymphoma
http://instagram.com/lymphomacommunity/
-
Category
No comments found